GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » 12-1 Month Momentum %

Shanghai Junshi Biosciences Co (HKSE:01877) 12-1 Month Momentum % : -61.96% (As of May. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-13), Shanghai Junshi Biosciences Co's 12-1 Month Momentum % is -61.96%.

The industry rank for Shanghai Junshi Biosciences Co's 12-1 Month Momentum % or its related term are showing as below:

HKSE:01877's 12-1 Month Momentum % is ranked worse than
82.14% of 1484 companies
in the Biotechnology industry
Industry Median: -22.325 vs HKSE:01877: -61.96

Competitive Comparison of Shanghai Junshi Biosciences Co's 12-1 Month Momentum %

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's 12-1 Month Momentum % falls into.



Shanghai Junshi Biosciences Co  (HKSE:01877) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Junshi Biosciences Co  (HKSE:01877) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Shanghai Junshi Biosciences Co 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines